Biopharma CEOs, investors call for same timeline for biologics, small molecules and lower out-of-pocket costs

Alzheimer’s and diseases like it have horrible costs on individuals, caregivers, and their families. A treatment for Alzheimer’s would not only relieve suffering for the patient and their family, but it would increase the productivity of millions of Americans and lower direct and indirect costs associated with care. And, once the treatment becomes generic, it will permanently upgrade human health for much less.